Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedDec 22, 2024
DataAggregated Company Financials
Companies567
- 7D-3.6%
- 3M-12.7%
- 1Y-2.6%
- YTD-6.5%
Over the last 7 days, the Biotech industry has dropped 3.6%, driven by a pullback from Vertex Pharmaceuticals of 14%. Over the last year, the industry has been flat overall. As for the next few years, earnings are expected to grow by 28% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 22 Dec 2024 | US$956.2b | US$149.9b | -US$26,389,992,070.38 | 15.7x | -36.2x | 6.4x |
| Tue, 19 Nov 2024 | US$990.8b | US$150.0b | -US$26,801,381,083.88 | 17.2x | -37x | 6.6x |
| Thu, 17 Oct 2024 | US$909.2b | US$113.1b | -US$36,028,650,557.25 | 21.9x | -25.2x | 8x |
| Sat, 14 Sep 2024 | US$913.2b | US$113.2b | -US$35,849,665,110.59 | 23.4x | -25.5x | 8.1x |
| Mon, 12 Aug 2024 | US$862.3b | US$112.7b | -US$36,815,169,721.78 | 21.6x | -23.4x | 7.7x |
| Wed, 10 Jul 2024 | US$1.1t | US$164.5b | -US$28,071,564,685.96 | 28.5x | -40.7x | 6.9x |
| Fri, 07 Jun 2024 | US$1.2t | US$164.6b | -US$26,702,448,993.85 | 28x | -43.3x | 7x |
| Sun, 05 May 2024 | US$1.1t | US$163.7b | -US$26,731,775,868.34 | 24.3x | -42x | 6.9x |
| Tue, 02 Apr 2024 | US$1.2t | US$164.5b | -US$23,680,262,586.04 | 24.1x | -49.8x | 7.2x |
| Thu, 29 Feb 2024 | US$1.2t | US$167.4b | -US$21,465,686,557.06 | 13.4x | -56.3x | 7.2x |
| Sat, 27 Jan 2024 | US$1.4t | US$204.7b | -US$22,646,483,045.00 | 18.3x | -63.4x | 7x |
| Mon, 25 Dec 2023 | US$1.4t | US$204.9b | -US$22,149,017,627.00 | 19.4x | -61.9x | 6.7x |
| Wed, 22 Nov 2023 | US$1.2t | US$204.7b | -US$22,046,246,661.00 | 18.1x | -55.4x | 6x |
| Fri, 20 Oct 2023 | US$1.2t | US$207.4b | -US$13,089,607,875.00 | 16.6x | -93.9x | 5.9x |
| Sun, 17 Sep 2023 | US$1.3t | US$207.5b | -US$12,865,929,372.00 | 17.5x | -99.8x | 6.2x |
| Tue, 15 Aug 2023 | US$1.3t | US$207.7b | -US$12,584,014,109.00 | 16.6x | -102.4x | 6.2x |
| Thu, 13 Jul 2023 | US$1.1t | US$186.5b | -US$15,948,766,717.00 | 13.2x | -70.8x | 6.1x |
| Sat, 10 Jun 2023 | US$1.1t | US$186.0b | -US$15,970,598,297.00 | 11.7x | -71.6x | 6.1x |
| Mon, 08 May 2023 | US$1.2t | US$192.6b | -US$12,085,119,722.00 | 15.6x | -97.1x | 6.1x |
| Wed, 05 Apr 2023 | US$1.2t | US$216.9b | -US$5,746,040,908.00 | 14.5x | -200.5x | 5.3x |
| Fri, 03 Mar 2023 | US$1.1t | US$199.0b | -US$5,026,926,227.00 | 15.3x | -226x | 5.7x |
| Sun, 29 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.8x | 668.9x | 5.7x |
| Tue, 27 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.5x | 703x | 5.7x |
| Thu, 24 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.6x | 868.7x | 5.6x |
| Sat, 22 Oct 2022 | US$1.1t | US$206.2b | US$5.3b | 15.8x | 200.9x | 5.2x |
| Mon, 19 Sep 2022 | US$1.1t | US$206.6b | US$5.9b | 14.7x | 182.2x | 5.2x |
| Wed, 17 Aug 2022 | US$1.1t | US$206.6b | US$7.2b | 16.4x | 155.4x | 5.4x |
| Fri, 15 Jul 2022 | US$1.1t | US$211.1b | US$10.6b | 16.9x | 101x | 5.1x |
| Sun, 12 Jun 2022 | US$957.4b | US$212.3b | US$11.1b | 15.6x | 86.5x | 4.5x |
| Tue, 10 May 2022 | US$971.1b | US$207.6b | US$9.6b | 13.5x | 100.7x | 4.7x |
| Thu, 07 Apr 2022 | US$1.3t | US$226.8b | US$14.3b | 18.6x | 90.8x | 5.7x |
| Sat, 05 Mar 2022 | US$1.2t | US$221.9b | US$10.2b | 18.9x | 117.5x | 5.4x |
| Mon, 31 Jan 2022 | US$1.2t | US$212.2b | US$2.5b | 23x | 495.5x | 5.8x |
| Wed, 29 Dec 2021 | US$1.4t | US$212.0b | US$2.8b | 25.9x | 512.4x | 6.7x |
Price to Earnings Ratio
512.4x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.2x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 11% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -2.37% | |
| Healthcare | -2.36% | |
| Biotech | -3.61% | |
| Biotech | -3.61% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$175.58 | 1.3% +US$3.9b | 13.3% | PE61.1x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| GILD Gilead Sciences | US$92.57 | 0.8% +US$891.1m | 16.2% | PE915.6x | |
| NBIX Neurocrine Biosciences | US$135.42 | 6.9% +US$882.9m | 5.4% | PE35.5x | |
| IMGN ImmunoGen | US$31.23 | 6.6% +US$516.6m | 617.9% | PS29.1x |
